drugset / Trial / NCT05828277
A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1 study to evaluate the effect of moderate or severe hepatic impairment on the PK of repotrectinib in patients with advanced cancer.
Timeline
- Start
- 2022-07-28
- Primary completion
- 2025-08-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Repotrectinib | Small molecule | — | Oral |